Loading...
•
Jun 30, 2023
Amicus Therapeutics Q2 2023 Earnings Report
Amicus Therapeutics reported strong growth of Galafold and regulatory approval of Pombiliti and Opfolda in the EU.
Key Takeaways
Amicus Therapeutics announced positive financial results for Q2 2023, with significant progress in Galafold growth and regulatory approvals for Pombiliti and Opfolda in the EU. The company revised its revenue guidance upwards and reduced operating expense guidance, supporting its path to non-GAAP profitability.
Galafold experienced strong growth.
Pombiliti and Opfolda received regulatory approval in the EU.
Revenue guidance was revised upwards.
Operating expense guidance was reduced.
Forward Guidance
Amicus Therapeutics is focused on key strategic priorities in 2023, including Galafold revenue growth and non-GAAP profitability.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...